CG Oncology appoints David Fela as vice president to strengthen quality control focus

CG Oncology appoints David Fela as vice president to strengthen quality control focus
CG Oncology taps new VP for quality

CG Oncology, Inc. has named David Fela as its new vice president of analytical development and quality control.

The appointment comes as the company advances its clinical programs with a focus on commercial readiness and maintaining rigorous analytical and quality standards. With Fela’s expertise, CG Oncology aims to uphold high standards as it moves closer to potential product commercialization.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.